Document:

Employment Agreement with Thomas G. Burger

 Exhibit 10.8 
 July 31, 2006 
 Personal and Confidential 
 Tom Burger 
 6 Fairway Drive 
 Hopewell, NJ 08525

 Dear Tom: 
 Aegerion Pharmaceuticals, Inc.
(“Aegerion” or the “Company”) is pleased to offer you the full-time position of Vice President of Business Development, reporting initially to Jerry Wisler. We are excited about the prospect of you joining our team, and look
forward to the addition of your professionalism and experience to help the Company achieve its goals. You are scheduled to begin your “at-will” employment with the Company on August 14, 2006. 
 Compensation and Benefits 
 You will be paid an initial
biweekly salary of $8,653.85 ($225,000 on an annualized basis) (the “Base Salary”), which will be paid in accordance with the Company’s normal payroll practices as established or modified from time to time. 
 In addition to your Base Salary, you will be eligible to earn a merit bonus of up to 25% of your Base Salary. The magnitude of the bonus, if any, will be determined by
the Company’s Board of Directors (the “Board”) and your manager in their sole discretion, based upon your achievement of a series of mutually agreed upon performance milestones. Your achievement of such milestones shall be
determined by the Board and your manager in their sole discretion. The bonus, if any, shall be paid at a time and in a manner as determined by the Company in its sole discretion. You must be employed by Aegerion in the role of Vice President of
Business Development at the time of any such bonus payment in order to be eligible for any such payment. 
 In addition, you will be granted an option to
purchase 300,000 shares of the Company’s common stock under the existing stock option program. The exercise price of the options will be at fair market value on your first date of employment. The terms of this grant shall be subject to and
governed by the Company’s stock plan and a Stock Option Agreement between you and the Company (the “Option Agreement”). 
 You will also be
eligible to participate in the Company’s benefits programs to the same extent as, and subject to the same terms, conditions and limitations applicable to, other employees of the Company of similar rank and tenure. These benefits presently
include: eligibility to accrue vacation time, paid holidays, a 401(k) plan and contributory health/dental insurance. For a more detailed understanding of the benefits and the eligibility requirements, please consult the summary plan descriptions for
the programs which will be made available to you during your new hire orientation. Please note that the Company may modify compensation and benefits at its discretion. 

 Certain Conditions of Employment 
 You will be required to sign the attached Business Protection Agreement as a condition of your employment with the Company. This Agreement is attached hereto as Exhibit A. You acknowledge that the Business
Protection Agreement shall remain in full force and effect regardless of any change in your position, compensation or any other term and conditions of your employment with the Company in accordance with the terms contained therein. 

In addition, you represent and warrant that your employment with the Company and the performance by you of your duties as an employee of the Company do not and will
not breach or contravene (i) any agreement or contract (including, without limitation, any employment or consulting agreement, any agreement not to compete or any confidentiality or nondisclosure agreement) to which you are a party; or
(ii) any obligation you may otherwise have under applicable law to any former employer or to any person to whom you have provided consulting services. You further represent and warrant that you have delivered or disclosed, as the case may be,
to the Company all agreements, contracts and obligations relevant to clauses (i) and (ii) above. In addition, you must execute the document attached hereto as Exhibit B as a condition of your employment. 
 Please note that as conditions of this offer and your employment you will need to complete an employment application, background and/or reference check to the
Company’s satisfaction, and you will need to execute the forms necessary for the processing of such background check. Moreover, please bring with you on your first day of employment for purposes of completing the I-9 form sufficient
documentation to demonstrate your eligibility to work in the United States. This verification must occur by the third day of your employment. 
 Severance Eligibility 
 In the event that your employment is terminated by the Company without Cause (as such term is defined in
Section 3(b) of the Option Agreement) at any time after the ninety (90) day period following your commencement date, you will be eligible to receive a severance package, provided that you (i) execute a comprehensive release agreement
in the Company’s favor, and (ii) comply with all post-employment restrictions, including those set forth in the Business Protection Agreement. Specifically, assuming that you meet the conditions set forth in sections (i) and
(ii) of this paragraph, you will be eligible to receive the following: (a) nine (9) months of your base monthly salary at the rate in effect at the time of such termination; and (b) if you elect after the termination date and in
accordance with the provisions of COBRA (or the New Jersey state law equivalent of COBRA, whichever is applicable) to continue health coverage under the same plans available to active Company employees, under the same rules, restrictions and
regulations applicable thereto, the Company shall make premium payments on your behalf until the earlier of (i) nine months from the date of termination, or (ii) the date on which you become ineligible to receive COBRA or state benefits
law benefits. Thereafter, you will be responsible for any such health insurance continuation payments. 
 Such severance payments and COBRA premiums will be
paid in substantially the same manner and form as the Company paid such salary and health insurance premiums in the three (3) month period preceding termination. It is intended that no severance or other payment pursuant to this 

 
offer letter will give rise to any adverse tax consequences pursuant to Section 409A of the Internal Revenue Code, as amended. The severance provision
herein shall be interpreted and applied to that end, and no effect shall be given to any provision herein in a manner that reasonably could be expected to give rise to adverse tax consequences under said Section 409A. Should there be a
reasonable possibility that a provision of this offer letter could give rise to such adverse tax consequences, any payments or other benefits under this policy shall be paid ‘as promptly as possible but without giving rise to any such adverse
consequences. 
 Your severance will be subject to set off or cessation in the event that you obtain other employment or consulting/contract work (whether
full-time or part-time) during such severance period (about which you agree to immediately advise the Company) or violate the release agreement or any post-employment restrictions. 
 In addition, please note that in the event that your employment is terminated by the Company for Cause, or in the event that you terminate your employment for any reason (including by reason of your death or
“Disability, as that term is defined in Section 3(a) of the Option Agreement), you will not be eligible for a severance package. 
 General

 The above terms are not contractual. They are a summary of our initial employment relationship and are subject to later modification by the
Company, except for the Company’s at-will policy, which cannot be modified. Please note that nothing in this offer letter is a promise or guarantee of employment for any specific period of time or continued employment. In this regard, the
Company has found that an at-will relationship is in the best interests of both the Company and its employees. As an at-will employee, either you or the Company can terminate your employment at any time and for any reason or no reason, with or
without prior notice. 
 We look forward to having you join Aegerion. We hope you will be a very valuable contributor to our team going forward. Please
provide a response to this letter within seven (7) days. 
 Sincerely, 
  

			
	By:	 	 /s/ Gerald Wisler

	Title:	 	President and Chief Executive Officer

 Enclosures 

 Exhibit A 
 Business Protection Agreement 

 BUSINESS PROTECTION AGREEMENT 
 This Agreement is entered by and between Aegerion Pharmaceuticals, Inc. (hereinafter the “Company”), and Tom Burger (hereinafter the
“Employee”), 
 WHEREAS, Employee acknowledges that he/she will be provided with the Company’s trade secrets and/or valuable
confidential business information, and, in addition, will develop, substantial relationships with, and be introduced to, prospective and existing customers and clients of the Company, and, as a result, shall benefit from the Company’s good
will; 
 WHEREAS, Employee acknowledges that he/she will receive training from the Company; 
 WHEREAS, this Agreement is a material part of the consideration of Employee’s employment with the Company, and the Company would not have hired
Employee but for Employee’s agreement to the terms and conditions of this Agreement; 
 WHEREAS, the Company is willing to employ
Employee, and Employee is willing to accept his/her employment with the Company, upon the terms and subject to the conditions hereinafter set forth herein; 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, Employee’s employment, and the compensation paid to Employee by the Company, the parties agree as follows:

 1. Employment At Will. 
 (a) Employee understands that neither this Agreement nor any other document or representation regarding employment with the Company constitutes an implied or written employment contract for continued employment with the Company. Rather,
Employee’s employment with the Company is on an “at-will” basis. Accordingly, Employee understands and agrees that either Employee or the Company may terminate Employee’s employment at any time and for any reason, with or without
cause and with or without notice. 
 (b) Employee will perform and carry out such duties and/or responsibilities as may from time to time be
assigned to Employee by the Company in its sole discretion. The Company may also modify or change Employee’s position, duties, compensation and responsibilities as it deems appropriate in its sole discretion. Any such changes shall not change
Employee’s obligations as set forth herein. During his/her employment with the Company, Employee shall devote his/her full business time and attention to the affairs of the Company. 
 (c) Employee understands, acknowledges and agrees that he/she is without any authority to enter into any contract or agreement on behalf of the Company
or to assume any obligation of any kin, express or implied, on behalf of the Company unless expressly authorized to do so by the Company in writing. 

 2. Employee’s Representations. 
 (a) Employee represents and warrants that he/she is qualified and uniquely skilled to perform the services required by the Company in accordance with the
standards of good professional practice and that Employee possesses all skills, qualifications and experience described in any application and/or resume submitted by Employee. Employee further understands and acknowledges that the Company relied
upon these representations in hiring Employee and that the Company would not have hired Employee but for these representations. 
 (b)
Employee represents that Employee’s employment with the Company and Employee’s performance of all of the terms of this Agreement do not, and will not, breach any agreement with any third party. Employee has not entered into, and Employee
shall not enter into, any agreement either written or oral in conflict herewith. 
 (c) Employee acknowledges that he/she owes to Company a
fiduciary duty of loyalty during the term of Employee’s employment and as may be otherwise provided by applicable law. 
 (d) Employee
agrees that at all times during and after his/her employment with the Company, Employee shall not disparage the Company, its products, services, agents and/or employees. 
 (e) If Employee is terminated for any reason, Employee will be able to earn a livelihood due to his/her sufficient capabilities without violating this Agreement. Employee understands that his/her ability to earn a
livelihood without violating this Agreement is a material condition of his/her employment with the Company. 
 3. Non-Solicitation of
Employees/Contractors. Employee agrees that during the course of his/her employment with the Company, and for the period of twelve (12) months following the termination of Employee’s employment (the “Restricted Period”),
regardless of the reason for the termination, Employee will not solicit, recruit or induce, in any manner, whether directly or indirectly, any “Person” to leave his or her employment or engagement with the Company. “Person” means
any person who (a) is employed (whether as an agent, representative, contractor or consultant by the Company) at the time this Agreement is terminated, (b) was employed by the Company during the year preceding termination of this
Agreement, or (c) is employed by the Company during the Restricted Period. 
 4. Non-Solicitation of/Non-Interference with
Customers. Employee agrees that during the Restricted Period, regardless of the reason for the termination, Employee will not, in any manner, on his own behalf or on behalf of another: 
 (a) solicit or do business with any customer or prospective customer of the Company with whom Employee had professional “Contact” during
Employee’s employment with the Company, for the purpose of providing or seeking to provide any products or services that relate, directly or indirectly, to the Company’s “Business” (as Defined in Section 5) (the
“Services”). “Contact” means any interaction, whether direct or indirect, between Employee and a Company customer or prospective customer that takes place in an effort to establish, maintain, service, provide Services and/or
further a business relationship on behalf of the Company; 

 (b) solicit or do business with any customer or prospective customer of the Company about whom Employee
obtained information, or became familiar with through Confidential Information (as defined in Section 6), during Employee’s employment with the Company, for the purpose of providing or seeking to provide Services; 
 (c) solicit or do business with any person or entity who has been a customer of the Company within the twenty-four (24) months preceding the date of
Employee’s termination for the purpose of providing or seeking to provide Services; and 
 (d) interfere in any way with the
Company’s relationship with any customer or prospective customer. 
 5. Noncompetition. 
 (a) Employee acknowledges that during his/her employment with the Company he/she shall be engaged in the Company’s “Business,” which
includes, but is not limited to, Cardiovascular and Metabolic drug development and commercialization (the “Business”). Employee also acknowledges and recognizes the highly competitive nature of the industry in which the Company is
involved, and agrees that he/she shall have access to the Company’s Confidential Information (as defined in Section 6), shall benefit from the Company’s goodwill and shall obtain a competitive advantage as to the Company, its
customers and prospective customers and its employees. 
 (b) Accordingly, ancillary to the agreement to hire Employee and provide Employee
with Confidential Information set forth in Section 6, Employee agrees that, during the Restricted Period, regardless of the reason for the termination, Employee shall not, directly or indirectly, anywhere in the world, alone or as a partner,
joint venturer, consultant, officer, director, employee, agent, or stockholder of any company or business organization or otherwise, engage in any business activity that (i) relates to the Business, or (ii) is in competition with the
Business, including, but not limited to, any Company product or service developed or being developed, planned or being planned, drafted or being drafted, marketed or being marketed, distributed or being distributed, sold or being sold, or otherwise
provided by the Company; provided however, that the record or beneficial ownership by Employee of 1% or less of the outstanding publicly traded capital stock of any such competing company shall not be deemed in and of itself to violate this
Section, so long as Employee exercises no operational or strategic control over such company. 
 6. Confidentiality. 
 (a) During Employee’s employment with the Company and at any time thereafter, Employee shall not disclose or use or otherwise exploit, for his/her
own benefit, or for the benefit of any other person or entity, any Confidential information (as defined in Section 6(b)). Employee acknowledges that all Confidential Information, together with all notes and records relating thereto and all
copies, electronic versions and facsimiles thereof, are the exclusive property of the Company. Employee shall return all such Confidential Information to the Company promptly upon request by the Company and, in any event, promptly upon any
termination or expiration of this Agreement. 

 (b) “Confidential Information” shall mean any of the trade secrets or confidential information
concerning the organization, business or finances of the Company and/or of any third party, including, but not limited to, clients and vendors, which the Company is under an obligation to keep confidential. Such Confidential Information shall
include, but is not limited to, trade secrets or confidential information respecting existing and future products and services, designs, methods, formulas, drafts of publications, research, clinical trial data, know-how, techniques, systems,
databases, processes, software programs or code, developments or experimental work, works of authorship, customer information, including, but not limited to any compilations of past, existing or prospective customers, customer proposals or
agreements between customers and the Company, status of customer accounts or credit, control sheets, sales techniques, or related information about actual or prospective customers, business plans, marketing plans, sales techniques, projects, the
Company’s salary and/or pay rates, other Company personnel information, and all other plans and/or proposals. “Confidential Information” shall not include information that (i) is or becomes a matter of public knowledge through no
fault or without violation of any duty of confidentiality of the Employee; or (ii) is rightfully received by the Employee from a third party without a duty of confidentiality. 
 (c) Employee agrees that during Employee’s employment Employee shall not make, use or permit to be used any Company Documentation (as defined in
Section 6(d)) otherwise than for the benefit of the Company. Employee further agrees that Employee shall not, after the termination of Employee’s employment for any reason, use or permit others to use any such Company Documentation, it
being agreed that all Company documentation shall be and remain the sole and exclusive property of the Company. Immediately upon the termination of .Employee’s employment for any reason Employee shall deliver all Company Documentation, and all
copies thereof, to the Company, at its main office. 
 (d) The term “Company Documentation” shall mean notes, drafts, research,
memoranda, manuscript, reports, proposals, business plans, marketing plans, lists, correspondence, records, drawings, sketches, blueprints, specifications, software programs, data, documentation or other materials of any nature and in any form,
whether written, printed, or in digital format or otherwise, relating to any matter within the scope of the business of the Company or concerning any of its dealings or affairs. 
 (e) Employee recognizes that the Company has received and in the future will receive from third parties, including, but not limited to, clients and
vendors, their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality. Of such information and to use it only for certain limited purposes. Employee agrees that Employee owes the Company
and such third parties, during the term of Employee’s employment and thereafter, regardless of the reason for Employee’s termination of employment, a duty to hold all such confidential or proprietary information in the strictest of
confidence and not to disclose it to any person, entity or corporation (except as necessary in carrying out Employee’s work for the Company consistent with the Company’s agreement with such third party) or to use it for the benefit of
anyone other than for the Company or such third party (consistent with the Company’s agreement with such third party) without the express written authorization of the Company. 

 (f) The confidentiality, property, and proprietary rights protections set forth in this Agreement are in
addition to, and not exclusive of, any and all other rights to which the Company is entitled under federal and state law, including, but not limited to, rights provided under copyright laws, trade secret and confidential information laws, and laws
concerning fiduciary duties. 
 (g) Employee agrees that Employee will not, during Employee’s employment with the Company, use or
disclose any proprietary information or trade secrets of Employee’s former employers or of any other third parties, and that Employee will not bring onto the premises of the Company any unpublished document or any property belonging to
Employee’s former employers or of any other third party, unless consented to in writing by said employers or third parties. By executing this Agreement, Employee indicates his/her understanding that any proprietary information or trade secrets
of any prior employer is not necessary to his/her employment by the Company. Moreover, Employee acknowledges that the Company is directing him/her not to rely on such proprietary information or trade secrets in the course of his/her employment, not
to disclose such information to the Company, and not to otherwise use such information. 
 (h) Employee specifically agrees and acknowledges
that the obligations of confidentiality described in this Section are retroactive to the beginning of his/her performance of any services for the Company and shall apply to Confidential Information received by him/her at any time. 
 (i) Employee agrees and acknowledges that during his/her employment with the Company and for the Restricted Period, Employee shall inform each
prospective new employer Employee may have, prior to accepting employment, of the existence of this Agreement, and shall provide each prospective employer with a copy of this Agreement. Employee agrees and acknowledges that the Company has the right
to independently contact any potential or actual future employer of mine to notify the future employer of my obligations under this Agreement and provide such future employer with a copy of this Agreement. The Company shall be entitled to notify
such actual or potential future employer of the Company’s understanding of the requirements of this Agreement and what steps, if any, the Company intends to take to insure compliance with or enforcement of this Agreement. In addition, Employee
shall execute the certification attached hereto as Exhibit A upon termination. 
 (j) Employee further understands and agrees
that in order for Company to protect its Confidential Information, the Company may at any time in its discretion, either with or without notice, audit and/or review files, materials and documents, computer hardware or software, email or voice
message systems which are provided to, utilized by and/or created by the Employee in the course of the performance of the Employee’s duties under this Agreement. 
 7. Ownership of Information and Documents. 
 (a) For purposes of this Agreement, “Work
Product” shall mean all information, including but not limited to, data, materials, text,, drawings, specifications, reports, notes, documentation, computer programs, inventions (whether or not patentable), records, business information, trade
secrets and all works of authorship (including, without limitation, all 

 
copyrights and trademarks existing therein), conceived and/or reduced to practice, created or developed by Employee, alone or jointly with others, related to
the business of Company or any client or conceived during work hours, at any time during Employee’s employment by the Company. Employee shall promptly and filly disclose to the Company any and all of such Work Product. All Work Product, whether
preliminary or final, tangible or intangible, shall be and remain the sole property of Company (unless assigned or licensed by the Company), and shall not be photocopied, reproduced or removed from the premises of Company or any client except as
required to perform duties under this Agreement or with the written permission of the client. All Work Product shall be delivered either to Company, or to the client upon request and, in any event, upon any termination or expiration of this
Agreement. Employee hereby releases any right, title and interest Employee may have to any Work Product during the term of this Agreement. To the extent the Work Product is not, by operation of law, considered work for hire for the Company, or
ownership of all right, title and interest of the intellectual property rights in the Work Product has not otherwise vested exclusively in Company, Employee hereby irrevocably assigns to Company, without further consideration, Employee’s entire
right, title, and interest in and to such Work Product. 
 (b) In this regard, Employee has attached hereto, as Exhibit B, a list
describing with particularity all intellectual property, including, but not limited to, property inventions, copyrights, copyright applications or registrations, original works of authorship, developments, improvements, patents, patent applications,
trademarks, trademark applications, trade names or trade secrets which were created or owned by Employee prior to the commencement of his employment and which belong solely to Employee or belongs to Employee jointly with another, which relate in any
way to any of the Company’s Businesses, products or research and development (collectively referred to as “Prior Inventions”), and which are not assigned to the Company hereunder; or, if no such list is attached, Employee represents
that there are no such Prior Inventions. If, in the course of employment, Employee agrees to incorporate into a Company product, process or machine a Prior Invention owned by him or in which he has an interest, absent a prior written agreement or
license between himself and the Company for such incorporation of the Prior Invention into a Company product, process or machine, then the Company is hereby granted and shall have anon-exclusive, royalty-free, irrevocable, perpetual, worldwide
license (with the right to sublicense) to make, have made, copy, modify, make derivative works of use, sell and otherwise distribute such Prior Invention as part of or in connection with such product, process or machine. 
 (c) Employee agrees to execute documents reasonable or necessary to vest all right, title, and interest in and to any Work Product, including, but not
limited to, patents, patent applications and trademark, and copyright filings. Employee shall maintain backup procedures during his/her employment with the Company to ensure that no data, documentation, program, text, specifications, notes, texts,
drawings or other information prepared by Employee on behalf of Company or any client are lost or destroyed. If the Company is unable, after reasonable effort, to secure Employee’s signature on any application for patent, copyright, trademark
or other analogous protection or other documents regarding any legal protection relating to Work Product, for any reason whatsoever, Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as
his/her agent and attorney-in-fact. to act for and in his/her behalf and stead to execute and file any such application or applications or other documents and to do all other lawfully permitted acts to further the prosecution and 

 
issuance of patent, copyright or trademark registrations or any other legal protection thereon with the same legal force and effect as if executed by
Employee. 
 (d) This provision shall not apply to an invention that Employee developed entirely on his or her own time without using the
Company’s equipment, supplies, facilities, or trade secret information except for those inventions that either: (i) relate at the time of conception or reduction to practice of the invention to the Company’s business, or actual or
demonstrably anticipated research or development of the Company; (ii) result from any work performed by Employee for the Company or any client; or (iii) result from Employee’s use of Company resources or Property. 
 8. Remedies. 
 (a) Employee
acknowledges that compliance with Sections 3, 4, 5, 6 and 7 hereof is necessary to protect the business and goodwill of die Company and that any breach of such Sections will irreparably and continually damage the Company in such a manner that
money damages will not be an adequate remedy. Consequently, Employee agrees that, in the event of any breach or threatened breach any of the covenants contained in Sections 3 through 7 hereof, the Company shall be entitled to a preliminary
and/or permanent injunction in order to prevent the continuation of such damage without having to prove actual damages. The Company may apply for such injunctive relief in any court of competent jurisdiction without the necessity of posting any bond
or other security. Nothing contained in this Agreement shall limit the Company’s right to any other remedies at law or in equity. 
 (b)
Employee agrees that if he/she violates any restrictive covenant in this Agreement (including Sections 3, 4 and 5) after his/her employment with the Company has terminated, the term of airy such covenant shall be tolled during the period of any
such violation. 
 9. Waiver of Rights. If, in one or more instances, either party shall fail to insist that the other party perform
any of the terms of this Agreement, such failure shall not be construed as a waiver by such party of any past, present or future right granted under this Agreement but the obligations of both parties under this Agreement shall continue in full force
and effect. This Agreement may not be modified except by an instrument in writing signed by the parties hereto. 
 10. Applicability and
Assignability. The Company shall have the right to assign this Agreement, or any rights and obligations hereunder to its successors and assigns, and all covenants and agreements hereunder shall inure to the benefit of and be enforceable by said
successors or assigns. Employee may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Company. 
 11. Indemnification. Employee, and Employee’s successors, assigns, executors, administrators and personal representatives, shall defend, indemnify and hold the Company harmless from and against any and all liabilities, losses,
damages, claims or demands whatsoever(including expenses, court costs and reasonable attorneys’ fees) asserted against or incurred by the Company as a result of or by reason of (a) the damage, destruction or theft of property, (b) the
death or injury of Employee or third persons, (c) Company having to defend any claim arising from Employee’s use of proprietary or trade secret information of a prior employer, 

 
and from any damages resulting from a final judgment or reasonable settlement of such claims, or (d) any negligence or intentional or willful act or
omission of Employee, including errors and omissions arising out of, through or during the performance of Employee’s duties under this Agreement. This indemnification shall include, but not be limited to, claims for infringement of patents,
trademarks or copyrights, misappropriation of trade secrets or Confidential Information, and/or breach of any restrictive covenants set forth herein, and is without prejudice to any of Company’s other rights or remedies at law. 
 12. Reimbursement. Employee hereby authorizes the Company at any time during or after the term of his/her employment to withhold from any amounts
otherwise owed to Employee (including, but not limited to, salary, bonus, commissions and expense reimbursements) to the fullest extent permitted by applicable law: any and all amounts due to the Company from Employee, including, but not limited to,
cash advances, draws, travel advances, overpayments made by the Company to Employee, amounts received by Employee due to the Company’s error, unpaid personal credit card or phone charges or any other debt Employee owes to the Company for any
reason, including amounts with respect to misuse or misappropriation of Company assets or breach of this Agreement. 
 13. Survival.
Sections 3-12, 14, 15 and 17 hereof shall survive any termination or expiration of this Agreement. 
 14. Severability. If any of
the provisions of this Agreement shall be invalid or unenforceable, such invalidity or unenforceability shall not invalidate or render unenforceable the remainder of this Agreement, but rather the remainder of this Agreement shall be construed as if
not containing the particular invalid or unenforceable provision or provisions, and the rights and obligations of the parties shall be enforced accordingly. Moreover, if one or more of the provisions contained in this Agreement shall for any reason
be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or provisions shall be construed by the appropriate judicial body by limiting, revising or reducing it or them, so as to be
enforceable to the maximum extent compatible with the applicable law as it shall then appear. Employee hereby further agrees that the language of all parts of this Agreement shall in all cases be construed as a whole according to its fair meaning
and not strictly for or against any of the parties. 
 15. Choice of Law. The construction, interpretation and performance of this
Agreement shall be governed and construed in accordance with the laws of the state of New Jersey, without giving effect to New Jersey’s principles of conflicts of laws. Any claims or legal actions by one party against the other shall
be commenced and maintained in any state or federal court located in New Jersey, and Employee hereby submits to the jurisdiction and venue of any such court. 
 16. Headings. The various headings in the Agreement are inserted for convenience only and shall have no effect on the interpretation of this Agreement or any part hereof. 
 17. Entire Agreement. This Agreement constitutes the entire Agreement between the parties hereto with respect to the subject matter hereof and
supersedes all prior understandings and agreements between the parties hereto relating to the subject matter hereof. Employee 

 
acknowledges that Employee is not entering into this Agreement in reliance upon any statement or representation except as otherwise expressly set forth
herein. 
 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the parties as of date first above written.

  

							
	EMPLOYEE	 		 	AEGERION PHARMACEUTICALS, INC.
				
	 /s/ Tom Burger
	 		 	By:	 	 /s/ Gerald Wisler

		 		 	Name:	 	Gerald Wisler
		 		 	Title:	 	President and CEO
				
	Date: July 31, 2006	 		 	Date:	 	August 11, 2006

 Exhibit B 
  

	TO:	Jerry Wisler 

 Aegerion Pharmaceuticals, Inc. 

1140 Route 22 East 
 Suite 304 

Bridgewater, NJ 08807 
  

	RE:	Acceptance of Employment 

 DATE: July 31, 2006 
 I represent that to the best or my understanding, I am under no common law or contractual obligation that would be an impediment to my employment with
Aegerion Pharmaceuticals, Inc. (the “Company”). I will not use or disclose any confidential, proprietary or trade secret information belonging to any former employer, in my employment with the Company. 
 I represent and warrant that I have not retained or copied any confidential, proprietary or trade secret information or property, in tangible or
electronic form, belonging to any former employer. 
 I agree that, if at any time during my employment with the Company, I am at risk of
using or disclosing any confidential, proprietary or trade secret information belonging to any former employer, I will immediately recuse myself from acting on the matter and advise the President of the Company, without revealing any protected
information, the nature of my conflict; provided, however, that I will not be required to recuse myself in the event such disclosure is required by law or regulation or as a result of a response to a valid order of a court or another governmental
body of the United States or any political subdivision thereof. 
 I understand that if any of the representations or warranties herein are
intentionally false, or if I violate any of the terms of this memorandum, that my employment will be terminated and that such, conduct may result in the forfeiture of any and all stock incentives (vested and unvested) awarded or issued to me at the
sole discretion of the Company and its Board of Directors. 
  

			
	Signature of Employee:	 	 /s/ Tom Burger

	Print Name of Employee:	 	Tom Burger

 Date: July 31, 2006 

 Amendment to Employment Agreement 
 This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT dated as of November 15, 2007 is between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), and Tom Burger (the “Executive”). 
 WHEREAS, the Executive is currently employed as a senior executive of the Company on the
terms set forth in a letter from the Company dated July 31, 2006 (the “Agreement”); 
 WHEREAS, the Agreement contains certain severance
provisions in respect of the Executive under the heading “Severance Eligibility”; and 
 WHEREAS, the parties hereto consider it appropriate that
the terms of the Executive’s employment be amended to prevent adverse tax treatment of severance payments to the Executive upon termination, and that such amendment be reflect in the terms set forth in the Agreement. 
 NOW, THEREFORE, the Company and the Executive agree to the following amendment to the terms of the Executive’s employment, as set forth in the Agreement.

  

	1.	Definitions. Capitalized terms used in this Amendment and not otherwise defined herein shall have the meaning given to such terms in the Agreement. 

  

	2.	In the first paragraph under the heading “Severance Eligibility”, the first sentence is amended by adding “within 21 days following delivery of the release
agreement to you” following “favor” in subpart (i). 

  

	3.	The section titled “Severance Eligibility” is further amended by adding a new paragraph to the end of the section that shall read as follows: 

 Anything in this letter to the contrary notwithstanding, if at the time of your termination of employment, you are considered a “specified
employee” within the meaning of Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as amended (the “Code”), and if any payment that you become entitled to under this Agreement is considered deferred compensation subject to
interest and additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, then no such payment shall be payable prior to the date that is the earliest of (i) six months
and one day after your date of termination, (ii) your death, or (iii) such other date as will cause such payment not to be subject to such interest and additional tax, and the initial payment shall include a catch-up amount covering
amounts that would otherwise have been paid during the first six-month period but for the application of this paragraph. 
  

	4.	Scope of Amendment. Except as expressly set forth in this Amendment, the Agreement remains in effect without modification. 

	5.	Counterparts. This Amendment may be executed and delivered (including by facsimile transmission) in one or more counterparts, and by different parties hereto in separate
counterparts, each of which when executed shall be deemed to be an original but all of which when taken together shall constitute one and the same agreement. 

 IN WITNESS WHEREOF, the Executive and the Company have executed this Amendment as of the date set forth above. 
 EXECUTIVE

  

	
	
	/s/ Tom Burger
	Name: Tom Burger

 AEGERION PHARMACEUTICALS, INC. 

	
	
	/s/ William H. Lewis
	 By: William H. Lewis
 Title: Chief Financial OfficerRestricted Stock Purchase Agreement with Gerald Wisler

 Exhibit 10.9 
 RESTRICTED STOCK PURCHASE AGREEMENT 
 THIS RESTRICTED STOCK PURCHASE AGREEMENT (this
“Agreement”) is entered into as of the 6th day of April, 2005, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and Gerald Wisler (the “Equity
Participant”). 
 W I T N E S S E T H: 
 WHEREAS, the Corporation desires to issue to the Equity Participant, and the Equity Participant desires to purchase from the Corporation, shares of the Corporation’s Common Stock, $0.001 par value per share (the
“Common Stock”). 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties do hereby agree as follows: 
 SECTION 1. Definitions. 
 As used in this Agreement, the following terms shall have the following respective meanings: 
 “Bridge Financing” shall have the meaning set forth in the Term Sheet. 
 “Cause” shall have the meaning set forth in the Consulting Agreement or Employment Agreement, as applicable. 
 “Code” shall mean the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder. 
 “Commission” shall mean the Securities and Exchange Commission or any other Federal agency administering the Securities Act at the
applicable time. 
 “Consideration” shall have the meaning set forth in Section 2.1. 
 “Consulting Agreement” shall mean the Consulting Agreement proposed to be entered into by and between the Corporation and the Equity
Participant. 
 “Employment Agreement” shall mean the Employment Agreement proposed to be entered into by and between the
Corporation and the Equity Participant pursuant to which the Equity Participant will be employed as the full-time Chief Executive Officer of the Corporation. 
 “Equity Stock” shall have the meaning set forth in Rule 3a11-1 under the Securities Exchange Act of 1934, as amended, and any successor statute and the rules and regulations thereunder, as shall be in
effect from time to time. 
 “Executive Commencement Date” shall have the meaning set forth in the Term Sheet. 

 “Fair Market Value” shall mean the fair market value, with respect to any Share, as
determined by the Board of Directors of the Corporation. 
 “Family” shall mean any spouse, lineal ancestor or descendant,
or sibling or any trust for the exclusive benefit of any of the foregoing and/or the Equity Participant. 
 “Group” shall
mean as to (a) a partnership, any or all of its general or limited partners or any “affiliate” thereof (as defined by Rule 405 promulgated under the Securities Act), (b) a trust, any of the beneficiaries, settlers or grantors now
existing or hereafter arising of, or any Person under common control with, such trust, (c) a corporation, any of its stockholders, any subsidiary of such corporation or any corporation which is under common control with such corporation, or any
directors, officers or employees of such corporation, and (d) a limited liability company, any of its members. 
 “Initial
Public Offering” shall mean the Corporation’s initial distribution of New Securities in an underwritten Public Offering to the general public pursuant to a registration statement filed with and declared effective by the Commission
pursuant to the Securities Act at a price per New Security of not less than the product of three (3) and the original purchase price per share for the Corporation’s initial round of Series A Preferred Stock (as adjusted for stock splits,
stock dividends or similar recapitalizations) and resulting in net proceeds to the Corporation of not less than $40 million. 
 “IRS” shall mean the Internal Revenue Service. 
 “New Securities” shall mean any Equity Stock,
including, but not limited to, shares of Common Stock, any security which is convertible into or exercisable or exchangeable for Common Stock, or any right, option or warrant to acquire any Common Stock. 
 “Original Cost Per Share” shall have the meaning set forth in Section 2.1. 
 “Person” shall mean and include a natural person, a corporation, a partnership, a limited liability company, a trust, an unincorporated
organization, an educational institution, a government or any department, agency or political subdivision thereof, or any other entity. 
 “Preferred Shares” shall mean, at the applicable time, all issued and outstanding shares, if any, of the Corporation’s preferred stock. 
 “Public Offering” shall mean a distribution of New Securities in a firm commitment underwritten public offering to the general public pursuant to a registration statement filed with and declared
effective by the Commission pursuant to the Securities Act. 
 “Released Shares” shall mean Shares that, in accordance with
Sections 3.1, 3.2 and 3.3, are no longer subject to repurchase by the Corporation pursuant to Section 4. 
 “Securities Act” shall mean the Securities Act of 1933, as amended, and any successor statute and the rules and regulations of the Commission thereunder, as shall be in effect at the applicable time. 
  

 2 

 “Shares” shall have the meaning set forth in Section 2.1. 
 “Term Sheet” shall mean the term sheet, dated as of February 28, 2005, by and between the Corporation and the Equity Participant.

 “Transfer” shall include any direct or indirect sale, assignment, transfer, pledge (but not including a pledge in favor
of the Corporation), hypothecation or other disposition of any Shares or of any legal or beneficial interest therein. 
 “Unreleased
Shares” means Shares that are not Released Shares. 
 SECTION 2. Issuance of Common Stock. 
 2.1 Subject to the terms and conditions contained herein, the Corporation hereby sells to the Equity Participant, and the Equity Participant hereby
purchases from the Corporation, 2,300,000 shares of Common Stock (the “Shares”) for a purchase price of $.001 per share (the “Original Cost Per Share”) or the aggregate purchase price of $2,300 (the
“Consideration”). Simultaneously with execution and delivery hereof, the Equity Participant is delivering to the Corporation a check or wire transfer of funds in the aggregate amount of the Consideration. 
 2.2 The Equity Participant, in his sole discretion, may make an effective election with the IRS under Section 83(b) of the Code and the regulations
promulgated thereunder in the form of Exhibit A attached hereto. The Equity Participant understands that under applicable law such election must be filed with the IRS no later than thirty (30) days after any acquisition of the Shares to
be effective. If the Equity Participant files an effective election, the excess of the fair value of the Shares (which the IRS may assert is different from the fair value determined by the Equity Participant) covered by such election over the amount
paid by the Equity Participant for the Shares shall be treated as ordinary income received by the Equity Participant. If the Equity Participant does not file an effective election, future appreciation on the Shares will generally be taxable as
ordinary income when the right of repurchase lapses as to such Shares pursuant to this Agreement. The foregoing is merely a brief summary of complex tax regulations, and therefore, the Equity Participant is strongly advised to consult with his own
tax advisors. 
 2.3 In the event that the Equity Participant files the election referred to in Section 2.2 above, the Equity
Participant will provide the Corporation with a copy of such election as filed. 
 SECTION 3. Repurchase Rights related to Common
Stock. 
 3.1 On the date hereof, 176,400 Shares shall immediately be released. 
 3.2 From the date of execution of this Agreement until the execution of the Employment Agreement, the Shares shall be released in a series of successive
equal daily installments of 1,575 shares. 
  

 3 

 3.3 Upon the execution of the Employment Agreement by the Equity Participant and the Corporation, the
Shares which remain unreleased after the release of those Shares pursuant to Sections 3.1 and 3.2 shall be released in accordance with the following table: 
  

			
	 Date of Vesting
	 	 Percentage of those unreleased Shares at the Executive Commencement
Date that remain unreleased

	 The first anniversary of the Executive
 Commencement Date
	 	75%
	 End of 1st
quarter after the first anniversary of
 Executive Commencement Date
	 	68.75%
	 End of 2nd
quarter after the first anniversary of
 Executive Commencement Date
	 	62.50%
	 End of 3rd
quarter after the first anniversary of
 Executive Commencement Date
	 	56.25%
	 End of 4th
quarter after the first anniversary of
 Executive Commencement Date
	 	50.00%
	 End of 1st
quarter after the second anniversary
 of the Executive Commencement Date
	 	43.75%
	 End of 2nd
quarter after the second anniversary
 of the Executive Commencement Date
	 	37.50%
	 End of 3rd
quarter after the second anniversary
 of the Executive Commencement Date
	 	31.25%
	 End of 4th
quarter after the second anniversary
 of the Executive Commencement Date
	 	25.00%
	 End of 1st
quarter after the third anniversary of the
 Executive Commencement Date
	 	18.75%
	 End of 2nd
quarter after the third anniversary of the
 Executive Commencement Date
	 	12.50%
	 End of 3rd
quarter after the third anniversary of the
 Executive Commencement Date
	 	6.25%
	 End of 4th
quarter after the third anniversary of the
 Executive Commencement Date
	 	0%

 3.4 In the event that the Equity Participant does not execute the Employment Agreement prior to or
in connection with the closing of the Bridge Financing or the Consulting Agreement with the Equity Participant is terminated by the Corporation for any reason (with or without Cause) other than the commencement of his full time employment with the
Corporation pursuant to the Employment Agreement, the Shares which remain unreleased at such time, after the release of those Shares pursuant to Sections 3.1 and 3.2, shall cease being released on the earlier of the date of the closing
of such Bridge Financing or the date of termination of the consulting arrangement, as applicable, and remain Unreleased Shares. 
 3.5
Notwithstanding the foregoing, in the event the Equity Participant’s employment is terminated without Cause in relation to the sale or other disposition of all or substantially all of the Corporation’s assets or a change in ownership in a
single transaction or series of related 

  

 4 

 
transactions of fifty percent (50%) or more of the Corporation’s stock, the Shares which remain unreleased at the time of termination, after the
release of those Shares pursuant to Sections 3.1 and 3.2 shall be released on the date of such termination and become Released Shares; provided, however that this provision shall not apply in the event of any equity financings of the
Corporation. 
 3.6 Except as provided for in Section 3.5 above, in the event the Equity Participant’s employment is
terminated without Cause, twenty-five percent (25%) of the Unreleased Shares on the date of such termination shall be released on the date of such termination and become Released Shares. 
 SECTION 4. Termination of Relationship. 
 4.1(a) In the event that the Equity Participant’s consulting is terminated for Cause prior to the execution of the Employment Agreement, the Corporation shall have the right to purchase from the Equity Participant, and if the
Corporation exercises its option pursuant to this Section 4, the Equity Participant shall sell to the Corporation upon the exercise of such right, all of the Equity Participant’s Unreleased Shares (rounded up to the nearest whole
Share) at the Original Cost Per Share. 
 (b) In the event that the Equity Participant executes the Employment Agreement prior to or in
connection with the closing of the Bridge Financing, and his employment is subsequently terminated for any reason (with or without Cause), the Corporation shall have the right to purchase from the Equity Participant, and if the Corporation exercises
its option pursuant to this Section 4, the Equity Participant shall sell to the Corporation upon the exercise of such right, (1) all of the Equity Participant’s Unreleased Shares (rounded up to the nearest whole Share) at the
Original Cost Per Share, and (2) all of the Equity Participant’s Released Shares (rounded up to the nearest whole Share) at the Fair Market Value per Share; provided, however, that if, after the Executive Commencement Date, the Equity
Participant’s employment is terminated by the Corporation for Cause pursuant to the terms and conditions of the Employment Agreement, the purchase price for any Released Shares shall be the Original Cost Per Share. 
 (c) For purposes of clause (b) above, Released Shares shall not include those shares that were released during the consulting period. 
 4.2 The number of Shares subject to purchase pursuant to Section 4.1 shall be adjusted to give effect to any stock dividend, or other
distribution of stock made on or in respect of such Shares, or any subdivision, combination or reclassification of the outstanding capital stock of the Corporation or received in exchange for the Shares. 
 4.3 In order to exercise the option to purchase the Equity Participant’s Shares under this Section 4, the Corporation shall deliver a
written notice to the Equity Participant (the “Share Repurchase Notice”), indicating its election to purchase any or all of the Shares and specifying the number of Unreleased Shares and Released Shares, if applicable, which the
Corporation elects to purchase and the purchase price therefor, within ninety (90) days after the Equity Participant’s termination. 
  

 5 

 4.4 The repurchase of Shares hereunder shall be made on a date within sixty (60) days of the
delivery of the Share Repurchase Notice, by delivery of payment to the Equity Participant, by check or wire transfer, against receipt of one or more certificates, properly endorsed, evidencing the Equity Participant’s Unreleased and/or Released
Shares, if applicable, to be so purchased. If the repurchase is not consummated by such date, the Corporation may deliver to the Equity Participant by check or wire transfer the applicable repurchase price for the Unreleased Shares and/or Released
Shares, if applicable, to be repurchased and may cancel the certificates evidencing such Unreleased Shares and/or Released Shares, if applicable, on the books and records of the Corporation. 
 4.5 Notwithstanding anything to the contrary contained in this Agreement, all repurchases of Shares by the Corporation shall be subject to applicable
restrictions contained in federal law, the Delaware General Corporation Law and in the Corporation’s debt and equity financing agreements. Notwithstanding anything to the contrary contained in this Agreement, if any such restrictions prohibit
or otherwise delay the repurchase of any Shares thereunder which the Corporation is otherwise entitled to make, the Corporation may make such repurchases within sixty (60) days of the date that it is permitted to do so under such restrictions.

 4.6 In the event that any Shares are the subject of repurchase by the Corporation pursuant to this Section 4, the Equity
Participant and his successors, assigns or representatives will take all steps necessary and desirable to obtain all required third-party, governmental and regulatory consents and approvals and take all other actions necessary and desirable to
facilitate consummation of such repurchase(s) in a timely manner as are requested by the Corporation. 
 SECTION 5. Legend on Shares
and Notice of Transfer. 
 5.1 Restrictive Legends. 
 (a) Each certificate evidencing Shares, and each certificate evidencing Shares held by subsequent transferees of any such certificate, shall (unless otherwise permitted by the provisions of Section 5.2
hereof) be stamped or otherwise imprinted with a legend in substantially the following form: 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAW. THESE SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR ANY EXEMPTION THEREFROM
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW. 
 (b) Each certificate evidencing Shares, and each
certificate evidencing Shares held by subsequent transferees of any such certificate, shall also be stamped or otherwise imprinted with a legend in substantially the following form: 
  

 6 

 ADDITIONALLY, THE TRANSFER OF THESE SECURITIES IS SUBJECT TO THE TERMS AND CONDITIONS OF A RESTRICTED
STOCK PURCHASE AGREEMENT EFFECTIVE AS OF APRIL 6, 2005, BETWEEN AEGERION PHARMACEUTICALS, INC. AND THE HOLDER OF RECORD OF THIS CERTIFICATE AND NO SALE, ASSIGNMENT, TRANSFER, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION OF SUCH SECURITIES SHALL BE
VALID OR EFFECTIVE EXCEPT IN ACCORDANCE WITH SUCH AGREEMENT AND UNTIL SUCH TERMS AND CONDITIONS HAVE BEEN FULFILLED. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE
SECRETARY OF AEGERION PHARMACEUTICALS, INC. 
 5.2 Notice of Transfer. 
 (a) The Equity Participant, and any other holder of any Shares by acceptance thereof, agrees that, prior to any Transfer of any Shares, such holder will
give written notice to the Corporation of such holder’s intention to effect such Transfer and to comply in all other respects with the provisions of this Section 5.2. Each such notice shall contain (i) a statement setting forth
the intention of said holder’s prospective transferee with respect to its retention or disposition of said Shares; and (ii) unless waived by the Corporation, an opinion of counsel for said holder as to the necessity or non-necessity for
registration under the Securities Act and applicable state securities laws in connection with such Transfer and stating the factual and statutory basis relied upon by counsel. The following provisions shall then apply: 
 (i) If the proposed Transfer of Shares may be effected without registration or qualification under the Securities Act and any applicable state securities
laws, then the registered holder of such Shares shall be entitled to Transfer such Shares in accordance with Section 5 hereof and the intended method of disposition specified in the statement delivered by said holder to the Corporation.

 (ii) If the proposed Transfer of such Shares may not be effected without registration under the Securities Act or registration or
qualification under any applicable state securities laws, the registered holder of such Shares shall not be entitled to Transfer such Shares pursuant to Section 6 until the requisite registration or qualification is effective.

 (b) Notwithstanding the provisions of Section 5.2(a), in the case of a Transfer by a holder to a member of such holder’s
Family or Group, no such opinion of counsel shall be necessary; provided, that the transferee agrees in writing to be subject to Section 5 hereof to the same extent as if such transferee were originally a signatory to this Agreement.

 (c) Each certificate evidencing the Shares issued upon such Transfer (and each certificate evidencing any untransferred balance of such
Shares) shall bear the legend set forth in Section 5.1(a) hereof unless (i) in the opinion of counsel (acceptable to the Corporation) 

  

 7 

 
addressed to the Corporation the registration of future Transfers is not required by the applicable provisions of the Securities Act or applicable state
securities laws; (ii) the Corporation shall have waived the requirement of such legend; or (iii) in the reasonable opinion of counsel to the Corporation, such Transfer shall have been made in connection with an effective registration
statement filed pursuant to the Securities Act or in compliance with the requirements of Rule 144 or Rule 144A (or any similar or successor rule) promulgated under the Securities Act, and in compliance with applicable state securities laws.

 (d) Each certificate evidencing the Shares issued upon such Transfer (and each certificate evidencing any untransferred balance of such
Shares) shall bear the legend set forth in Section 5.1(b) hereof for so long as this Agreement remains in effect. In the event of the termination of this Agreement, the holder of Shares may request that the Corporation issue a new
certificate not bearing the legend set forth in Section 5.1(b) hereof. 
 SECTION 6. Covenants of the Equity Participant
and the Corporation. 
 6.1 Permitted Transfers. 
 (a) Neither the Equity Participant nor any permitted transferee of the Equity Participant shall Transfer all or any of the Shares to any Person except in accordance with Sections 3 and 4 hereof.
Notwithstanding anything to the contrary contained herein (other than Section 3 hereof), the Equity Participant (and any permitted transferee of the Equity Participant) may Transfer all or any portion of his Shares: (i) if the
stockholder is a limited partnership or a trust, to any member of the Group of which the Equity Participant (or such permitted transferee) is a member; provided, that such transferee shall agree in writing with the Corporation, prior to and as a
condition precedent to such Transfer, to be bound by all of the provisions of this Agreement (ii) if the stockholder is a corporation or a limited liability company, to any member of its Group; provided, that such transferee shall agree in
writing with the Corporation, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of this Agreement; (iii) if the stockholder is an individual, to any member of the Family of such stockholder; provided,
that such new transferee shall agree in writing with the Corporation, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of this Agreement and, provided, further, that the interests in any Family trusts
shall be nontransferable; and (iv) if the transferor is a permitted transferee of the Equity Participant by will or the laws of descent and distribution, provided that each such new transferee shall be bound by all of the provisions of this
Agreement to the same extent as if such transferee was a party hereto. 
 (b) If requested in writing by the managing underwriters, if any,
of any Initial Public Offering, the Equity Participant agrees not to offer, sell, contract to sell or otherwise dispose of any Shares except as part of such Initial Public Offering within thirty (30) days before or one hundred and eighty
(180) days after the effective date of the registration statement filed with respect to said offering; provided, however, that this restriction will not apply to transfers permitted under Section 6.1(a) provided such transferee
agrees to be bound by the restriction contained in this Section 6.1(b). 
  

 8 

 6.2 Right of First Offer on Dispositions. 
 (a) If Equity Participant desires to Transfer all or any part of his Shares pursuant to this Section 6.2 at any time prior to completion of
the Corporation’s Initial Public Offering (other than pursuant to Section 6.1(a) or 6.3 hereof), Equity Participant shall submit a written offer (the “Offer”) to sell such Shares (the “Offered Shares”) to
the Corporation, which Offer shall specify the number of Offered Shares proposed to be sold, the total number of Shares owned by Equity Participant, and the terms and conditions, including price, at which the Shares are being offered. 
 (b) The Corporation shall have the right to purchase any or all of the Offered Shares on the same terms and conditions specified in the Offer.

 (c) If the Corporation desires to purchase any or all of the Offered Shares on the same terms and conditions specified in the Offer, the
Corporation shall deliver its acceptance (an “Acceptance”) to Equity Participant, which Acceptance shall confirm that the Corporation desires to purchase any or all of the Offered Shares and the number of Shares the Corporation
desires to purchase and shall be delivered in person or mailed to Equity Participant at the address set forth in the Offer within twenty (20) days of the date the Offer was made by Equity Participant pursuant to Section 6.2(a).

 (d) If the Corporation elects to purchase any or all of the Offered Shares, sale of the Offered Shares pursuant to this
Section 6.2 shall be made at the offices of the Corporation on the 30th day following the expiration of the 20-day period described above (or if such 30th day is not a business day, then on the next succeeding business day). Such sale
shall be effected by Equity Participant’s delivery to the Corporation of a certificate or certificates evidencing the Offered Shares to be purchased by it, duly endorsed for transfer to the Corporation, which Offered Shares shall be delivered
free and clear of all liens, charges, claims and encumbrances of any nature whatsoever, against payment to Equity Participant of the purchase price therefor by the Corporation. Payment for the Offered Shares shall be made as provided in the Offer or
by wire transfer or certified check. 
 (e) If the Corporation does not elect to purchase all of the Offered Shares, then the Offered Shares
(less the amount to be purchased by the Corporation) may be sold by Equity Participant at any time within one hundred twenty (120) days after the date the Corporation responded to the Offer was made by Equity Participant pursuant to
Section 62(a). Any such sale shall be upon terms and conditions, including price, no more favorable to the proposed transferee than those specified in the Offer. Any Offered Shares not sold within such 120-day period shall continue to be
subject to the requirements of a prior offer pursuant to this Section 6.2. 
 6.3 Drag Along. Subject to
Section 6.2 above, anything in this Agreement to the contrary notwithstanding, in the event that (i) the Board of Directors of the Corporation by unanimous vote or unanimous written consent and/or the holders of more than fifty
percent (50%) of the then outstanding Common Stock by vote or written consent approves a transaction pursuant to which any Person or Persons not affiliated with any of the holders of any Common Stock will acquire fifty percent (50%) or
more of the Common Stock of the Corporation (by stock purchase, merger or otherwise) or all or substantially all of the assets of the Corporation, upon the written request of the holders of more than fifty percent (50%) of the Common Stock,

  

 9 

 
the Equity Participant agrees to offer to sell all of his Shares, and to sell all of his Shares (or, if such proposed transaction involves the sale of less
than one hundred percent (100%) of the outstanding Common Stock, a proportionate amount of his Shares), to such Person or Persons or to vote all of his Shares in favor of the sale of assets, as the case may be, in either case upon the terms and
conditions of the transaction approved by the Board of Directors of the Corporation and/or the holders of more than fifty percent (50%) of the Common Stock; provided, however, that the Equity Participant’s obligation to sell his Shares
pursuant to this Section 6.3 shall only apply if all of the Shares are to be sold on the same terms and conditions as the shares of such other Person or Persons. For purposes of this Section 6.3, each Preferred Share shall be
deemed to be the number of shares of Common Stock into which such Preferred Share is then convertible. 
 6.4 “Piggyback”
Registrations. (a) If the Corporation at any time proposes to register any of its securities under the Securities Act on Form S-1, S-2 or S-3 or on any other form upon which the Common Stock may be registered for sale to the general public,
other than on Form S-4 or S-8 or other similar registration statement not generally used by an issuer in connection with raising capital, whether for its own account or for the account of others, the Corporation will at each such time promptly give
written notice to the Equity Participant of such proposal, which shall set forth information, to the extent then known, as to offering price or range, the number of shares to be offered, the proposed manner of distribution and the proposed managing
underwriter(s) of the offering. Upon the written request of the Equity Participant given within twenty (20) days after the Corporation has given such notice and subject to any rights of the holders of Preferred Shares of the Corporation, the
Corporation will cause the Shares which the Corporation has been requested to register by the Equity Participant to be registered under the Securities Act (and any related qualification under blue sky laws or other compliance), all to the extent
required to permit the sale or other disposition by the Equity Participant of the Shares so registered. 
 (b) If securities are to be
registered for sale under a registration and are to be distributed for the account of the Corporation by or through a firm of underwriter(s), then, subject to the rights of the holders of Preferred Shares of the Corporation, any Shares which the
Corporation has been requested to register pursuant to clause (a) of this Section 6.4 shall also be included in such underwriting on the same terms as other securities of the same class as the Shares included in such underwriting;
provided, that if, in the written opinion of the managing underwriter(s), the total amount of such securities to be so registered, when added to the Shares, will exceed the maximum amount of the Corporation’s securities which can be marketed
(i) at a price reasonably related to their then current market value, or (ii) without otherwise materially and adversely affecting the entire offering, then (subject to clause (d) of this Section 6.4) the Corporation shall
exclude from such underwriting, first, the number of Shares being sold for the account of the Equity Participant as is necessary, in the opinion of the managing underwriter(s), to reduce the size of the offering provided, however, that
the number of securities to be requested to be sold in the offering by officers, directors and other founding stockholders are likewise reduced pro rata based upon the number of securities requested to be registered. 
 (c) If securities are to be registered for sale under a registration and are to be distributed for the account of holders of Common Stock held by third
parties or holders (other than the Corporation) of other securities of the Corporation other than Common Stock by or 

  

 10 

 
through a firm of underwriters) of recognized standing under underwriting terms appropriate for such transaction, then any Shares which the Corporation has
been requested to register pursuant to clause (a) of this Section 6.4 shall also be included in such underwriting on the same terms as other securities included in such underwriting, provided, that if, in the written opinion of the
managing underwriter(s), the total amount of such securities to be so registered, when added to such Shares, will exceed the maximum amount of the Corporation’s securities which can be marketed (i) at a price reasonably related to their
then current market value, or (ii) without otherwise materially and adversely affecting the entire offering, then the Corporation shall exclude from such underwriting the number of Shares and other securities, pro rata to the extent
practicable, on the basis of the number of securities requested to be registered, as is necessary in the opinion of the managing underwriter(s) to reduce the size of the offering; provided, however, that the number of securities to be
requested to be sold in the offering by officers, directors and other founding stockholders are likewise reduced pro rata based upon the number of securities requested to be registered. 
 (d) Notwithstanding Sections 6.4(a) and (b) and (c), the Corporation may exclude all Shares from registration in connection
with the Corporation’s Initial Public Offering if the inclusion of such Shares would, in the written opinion of the managing underwriter(s) adversely affect the marketing of the New Securities to be sold by the Corporation therein; provided
that such exclusion of Shares shall be made pro rata with all other shares of Common Stock held by third parties issued prior to the issuance and sale of the Preferred Shares; provided, further, that such shares of Common Stock shall not include
shares of Common Stock received by third parties pursuant to conversion of Preferred Shares. 
 SECTION 7. Representations.

 7.1 Representations of the Equity Participant. In connection with the Equity Participant’s purchase of any Shares on the date
hereof, the Equity Participant hereby represents and warrants to the Corporation as follows: 
 (a) Investment Intent; Capacity to Protect
Interests. The Equity Participant is acquiring the Shares solely for his own account for investment and not with a view to or for sale in connection with any distribution of the Shares or any portion thereof and not with any present intention of
selling, offering to sell or otherwise disposing of or distributing the Shares or any portion thereof in any transaction other than a transaction exempt from registration under the Securities Act. 
 (b) Restricted Securities. The Equity Participant understands and acknowledges that the sale of the Shares has not been registered under the
Securities Act; that the Shares must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; and that, except as provided in Section 6.3, the Corporation is under
no obligation to register the Shares. The Equity Participant has no need for liquidity relating to his investment in the Shares and is able to bear the economic risk of his investment in the Shares for an indefinite period of time. 
  

 11 

 (c) Disposition under Rule 144. The Equity Participant understands that the Shares are restricted
securities within the meaning of Rule 144 promulgated under the Securities Act; that the exemption from registration under Rule 144 will not be available in any event for at least one (1) year from the date of purchase of any payment for the Shares,
and even then will not be available unless (i) a public trading market then exists for the Shares, (ii) adequate information concerning the Corporation is then available to the public, and (iii) other terms and conditions of Rule 144 are complied
with; and that any sale of the Shares may be made only in limited amounts in accordance with such terms and conditions. 
 (d) The Equity
Participant has generally such knowledge and experience in business and financial matters and with respect to investments in securities of privately held companies so as to enable him to understand and evaluate the risks and benefits of his
investment in the Shares. The Equity Participant has had an opportunity to ask questions and receive answers concerning the terms and conditions of the offering of the Shares and has had full access to or been provided with such other information
concerning the Corporation as he has requested. 
 7.2 Representations of the Corporation. The Corporation represents to the Equity
Participant that: 
 (a) The execution, delivery and performance by the Corporation of this Agreement and all transactions contemplated by
this Agreement have been duly authorized by all action required by law, its Certificate of Incorporation, its Bylaws or otherwise. 
 (b)
This Agreement has been duly executed and delivered by the Corporation and constitutes the legal, valid and binding obligation of the Corporation enforceable against it in accordance with its terms. 
 SECTION 8. Withholding. Upon the request of the Corporation, the Equity Participant shall promptly pay to the Corporation, or make arrangements
satisfactory to the Corporation regarding payment of, any Federal, state or local taxes of any kind required by law to be withheld with respect to the Shares (or any distributions of other securities or property (including cash) thereon or issued in
replacement thereof). 
 SECTION 9. Remedies. In case any one or more of the covenants and/or agreements set forth in this Agreement
shall have been breached by any party hereto, the party entitled to the benefit of such covenants or agreements may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including, but not limited to, (a) an
action for damages as a result of any such breach, (b) an action for specific performance of any such covenant or agreement contained in this Agreement, and/or (c) a temporary or permanent injunction, in any case without showing any actual damage.
The rights, power and remedies of the parties under this Agreement are cumulative and not exclusive of any other agreement or law. No single or partial assertion or exercise of any right, power or remedy of a party hereunder shall preclude any other
or further assertion or exercise thereof. Any purported Transfer in violation of the provisions of this Agreement shall be null and void ab initio. 
  

 12 

 SECTION 10. Successors and Assigns. Except as otherwise expressly provided herein, this Agreement
shall bind and inure to the benefit of the Corporation, the Equity Participant, the respective successors or heirs, distributees and personal representatives and permitted assigns of the Corporation and the Equity Participant, and each other person
who shall properly become a registered holder of any Shares that have not theretofore been sold to the public pursuant to a registration statement under the Securities Act or Rule 144 or Rule 144A (or any similar or successor rule). 
 SECTION 11. Entire Agreement. This Agreement, together with the Term Sheet and the Confidentiality and Assignment Agreement executed by the
parties, contain the entire agreement among the parties with respect to the subject matter hereof and supersede other prior and contemporaneous arrangements or understandings with respect thereto. 
 SECTION 12. Notices. All notices, consents and other communications under this Agreement shall be in writing and shall be deemed to have been duly
given (a) when delivered by hand, (b) one (1) business day after the business day of transmission, if sent by telex or telecopier (with receipt confirmed), provided that a copy is mailed by registered mail, return receipt requested, or (c) one (1)
business day after the business day of deposit with the carrier, if sent by Express Mail, Federal Express or other nationally-recognized express delivery service (receipt requested), in each case to the appropriate addresses, telex numbers and
telecopier numbers set forth below (or to such other addresses or telecopy numbers as a party may designate as to itself or herself by notice to the other party): 
  

	 	(a)	If to the Equity Participant: 

 Gerald Wisler 

c/o Aegerion Pharmaceuticals, Inc. 
 250
West Main Street 
 Branford, Connecticut 06405 
  

	 	(b)	If to the Corporation: 

 Aegerion Pharmaceuticals, Inc.

 c/o Scheer & Company, Inc. 
 250 West Main Street 
 Branford, Connecticut 06405 
 Telecopier: (203) 481-4164 
 Attention: David I. Scheer, President 
 with a copy to: 
 Sills Cummis Epstein
& Gross P.C. 
 One Riverfront Plaza 
 Newark, New Jersey 07102 
 Telecopier No.: (973) 643-6500 
 Attention: Ira A. Rosenberg, Esq. 
  

 13 

 SECTION 13. Changes. The terms and provisions of this Agreement may not be modified or amended, or
any of the provisions hereof waived, temporarily or permanently, without the prior written consent of each of the parties hereto. 
 SECTION
14. Counterparts. This Agreement may be executed in any number of counterparts, and each such counterpart shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement and that execution
may be delivered by facsimile. 
 SECTION 15. Headings. The benefits of the various sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed to be part of this Agreement. 
 SECTION 16. Nouns and Pronouns. Whenever the
context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa. 
 SECTION 17. Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability. Such prohibition or unenforceability in any one jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 
 SECTION 18. Governing Law; Jurisdiction. This Agreement and (unless otherwise provided) all amendments hereof and waivers and consents hereunder
shall be governed by the internal law of the State of Delaware, without regard to the conflicts of law principles thereof. Each party hereby submits itself or himself, for the sole purpose of this Agreement and any controversy arising hereunder, to
the exclusive jurisdiction of the state and Federal courts located in the State of Connecticut, and waives any objection (on the grounds of lack of jurisdiction, forum non conveniens or otherwise) to the exercise of such jurisdiction over it or him
by any such court in the State of Connecticut. Each party hereby agrees that service of process may be served on it or him by certified mail, return receipt requested, or overnight courier, sent to the address of such entity or such entity’s
attorneys listed in Section 12 above (or such other address as any such party notifies the other thereof by written notice). 
 IN WITNESS
WHEREOF, the parties hereto have executed this Restricted Stock Purchase Agreement as of the date and year first written above. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	/s/ David Scheer
		 	Name: David Scheer
		 	Title: Chairman

  

 14 

	
	 /s/ Gerald Wisler

	 Gerald Wisler

  

 15 

 Exhibit A 
 Form of 83(b) Election 
 ELECTION PURSUANT TO SECTION 83(b) OF THE 
 INTERNAL REVENUE CODE 
 The undersigned hereby
makes the election authorized by Section 83(b) of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations thereunder, with respect to shares of Common Stock of Aegerion Pharmaceuticals, Inc.
(the “Company”) described below acquired by the undersigned on the date shown below. To the extent permitted, this election shall also serve as an election under analogous state law. As required by the Treasury Regulations
under Section 83(b), the undersigned supplies herewith the following information: 
  

	1.	The undersigned’s name and address are: 

 Name: 
 Address: 
  

	2.	The undersigned has taxpayer identification number             ; 

  

	3.	The property with respect to which this protective election is made consists of              shares of Common
Stock of the Company. 

  

	4.	The date on which the above-described property was transferred to the undersigned was             .

  

	5.	As of the date of transfer, the property was subject to the following substantial risk of forfeiture: 

 (a) All of the shares are subject to time vesting based on a continued business relationship with the Company. 
 (b) All of the shares which have not been “released” are subject to repurchase by the Company in the event the
undersigned’s business relationship with the Company ceases for any reason. The purchase price for each share of Common Stock which has not yet been “released” and is subject to repurchase will be the undersigned’s original cost
per share. 
 (c) All of the shares which have been “released” are subject to repurchase by the Company in the event
the undersigned’s business relationship with the Company is terminated for Cause. The purchase price for each share of Common Stock which has been “released” and is subject to repurchase will be the undersigned’s original cost
per share. 
 (d) All of the shares which have been “released” are subject to repurchase by the Company in the event
the undersigned’s business relationship with the Company 

  

 16 

 
ceases for any reason other than Cause. The purchase price for each share of Common Stock which has been “released” and is subject to repurchase
will be the fair market value of such share. 
  

	6.	The fair market value of the property at the time of transfer (determined without regard to any restrictions other than restrictions which by their terms will never lapse) was
$            per share. 

  

	7.	The amount paid for the property by the undersigned was $0.001 per share (“Original Cost Per Share”). 

 A copy of this election has been furnished to the Company, and a copy of this election will be attached to the undersigned’s federal income tax
return for the year to which this election relates. 
  

	
	  

	 Name:

	 Date:                                     
                                        
          

  

 17 

 Amendment No. 1 to Restricted Stock Purchase Agreement 
 This Amendment No. 1 to Restricted Stock Purchase Agreement (the “Amendment”) is made as of this 13 day of June 2007, by and
between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”) and Gerald Wisler (the “Equity Participant”), parties to that certain Restricted Stock Purchase Agreement dated as of April 6,
2005 (the “Agreement”). Capitalized terms used herein, unless otherwise defined herein, shall have the meanings ascribed to them in the Agreement. 
 WHEREAS, the Corporation and the Equity Participant desire to amend the Agreement; and 
 WHEREAS, pursuant to Section 13 of the Agreement, a waiver, amendment or modification to the terms and provisions of the Agreement may not be effected without the prior written consent of the Corporation and the Equity
Participant. 
 NOW, THEREFORE in consideration of the foregoing and intending to be legally bound, the Company and the Equity
Participant agree as follows. 
 1. The definition of “Initial Public Offering” contained in Section 1 of the Agreement is amended and
restated in its entirety to read as follows: 
 “Initial Public Offering” shall mean the Corporation’s initial
distribution of New Securities in a firm commitment underwritten public offering to the general public pursuant to a registration statement filed with and declared effective by the Commission pursuant to the Securities Act. 
 2. Section 6.3 of the Agreement shall terminate upon an Initial Public Offering. 
 3. This Amendment shall be deemed to be a contract made under, and shall be construed in accordance with, the laws of the State of Delaware, without giving effect to conflict of interest laws principles thereof.

 4. This Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and
the same instrument. 
 5. Except to the extent amended hereby, the terms and provisions of the Agreement shall remain in full force and effect. 

[SIGNATURE PAGE FOLLOWS] 
  

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 to Restricted Stock
Purchase Agreement as of the date and year first written above. 
 AEGERION PHARMACEUTICALS, INC. 
 By /s/ William Lewis 
 Name: William Lewis 
 Title: Chief Financial Officer 
 /s/ Gerald Wisler 
 Gerald Wisler

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]